Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

Rhea-AI Summary

Vigil Neuroscience, Inc. (Nasdaq: VIGL) will present at the Citizens JMP Life Sciences Conference, showcasing their focus on harnessing microglia for treating neurodegenerative diseases. The management's participation in a fireside chat is scheduled for May 14th at 11:30 a.m. E.T. Interested individuals can register for the live event on the company's website. The webcast will also be accessible via the website for 90 days post-presentation.

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T.

To register for the live event, please click here. The webcast will also be available on the Company’s website on the “Events & Presentations” page in the “Investors” section. An archived webcast will be available for approximately 90 days following the presentation.

About Vigil Neuroscience

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Internet Posting of Information

Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.

Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com

Media Contact:
Megan McGrath
MacDougall Advisors
mmcgrath@macdougall.bio   

FAQ

When will Vigil Neuroscience present at the Citizens JMP Life Sciences Conference?

Vigil Neuroscience will present at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T.

What is the focus of Vigil Neuroscience's presentation at the conference?

Vigil Neuroscience will showcase their focus on harnessing the power of microglia for the treatment of neurodegenerative diseases.

Where can individuals register for the live event presentation?

Interested individuals can register for the live event on the Company’s website.

How long will the webcast of the presentation be available for viewing?

An archived webcast of the presentation will be available for approximately 90 days following the event.